Стероидная глаукома
https://doi.org/10.30629/0023-2149-2021-99-7-8-420-428
Аннотация
Глюкокортикостероиды широко применяются как в общеклинической, так и в офтальмологической практике. Однако их неоправданное использование недопустимо, а назначения должны строго контролироваться и требуют мониторинга уровня внутриглазного давления, так как одними из установленных побочных эффектов препаратов этого ряда являются повышение уровня офтальмотонуса и развитие глаукомной оптиконейропатии. В данном обзоре рассмотрен патогенез повышения уровня внутриглазного давления на фоне приема различных форм глюкокортикостероидов, описано время и продолжительность их офтальмогипертензивного действия. Подробно изучены имеющиеся данные об особенностях клинической картины стероидной глаукомы в зависимости от путей их введения. Описана тактика лечения пациентов с офтальмогипертензией или установленным диагнозом стероидной глаукомы.
Ключевые слова
Об авторах
З. М. Нагорнова
ФГБОУ ВО «Ивановская государственная медицинская академия» Минздрава России
Россия
Россия
Нагорнова З.М., ассистент кафедры оториноларингологии и офтальмологии
153012, Иваново
А. В. Селезнев
ФГБОУ ВО «Ивановская государственная медицинская академия» Минздрава России
Россия
Россия
Селезнев А.В., канд. мед. наук, доцент кафедры оториноларингологии и офтальмологии
153012, Иваново
И. А. Булах
ООО «МЦ Ивастрамед»
Россия
Россия
Булах И.А., врач-офтальмолог
153021, Иваново
А. Ю. Брежнев
ФГБОУ ВО «Курский государственный медицинский университет» Минздрава России
Россия
Россия
Брежнев А.Ю., канд. мед. наук, доцент кафедры офтальмологии
305041, Курск
А. В. Куроедов
ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России; ФКУ «Центральный военный клинический госпиталь им. П.В. Мандрыка» Минобороны России
Россия
Россия
Куроедов А.В., д-р мед. наук, начальник отделения, профессор кафедры офтальмологии
117997, Москва; 107014, Москва
Список литературы
1. Kiernan D.F., Mieler W.F. Intraocular corticosteroids for posterior segment disease: 2012 update. Expert Opin Pharmacother. 2012;13(12):1679–1694. DOI: 10.1517/14656566.2012.690736
2. Kiddee W., Trope G.E., Sheng L. et al. Intraocular pressure monitoring post intravitreal steroids: a systematic review. Surv. Ophthalmol. 2013;58(4):291–310. DOI: 10.1016/j.survophthal.2012.08.003
3. Куроедов А.В., Мовсисян А.Б., Егоров Е.А. и др. Профиль пациентов с первичной открытоугольной глаукомой в Российской Федерации (предварительные результаты многоцентрового популяционного исследования). Часть 1. Национальный журнал глаукома. 2021;20(1):3–15.
4. Егоров Е.А., Петров С.Ю., Городничий В.В. и др. Тонометрическое внутриглазное давление у взрослого населения: популяционное исследование. Национальный журнал глаукома. 2020;19(2):39–50.
5. McLean J. MUse of ACTH and cortisone. Trans. Am Ophthalmol. Soc. 1950;48:293–296.
6. Bernstein H.N., Mills D.W., Becker B. Steroid-induced elevation of intraocular pressure. Arch. Ophthalmol. 1963;70:15–18. DOI: 10.1001/archopht.1963.00960050017005
7. Francois J. Cortisone et tension oculaire. Ann. D’Ocu list.1954; 187(9):805.
8. Tham Y.C., Li X., Wong T.Y., Quigley H.A. et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090. DOI: 10.1016/j.ophtha.2014.05.013
9. Smith C.L. Corticosteroid glaucoma: A summary and review of the literature. Am. J. Med. Sci. 1966;252(2):239–244. DOI: 10.1097/00000441-196608000-00017.
10. Нестеров А.П. Глаукома. М.: МИА, 2008:357.
11. Jobling A.I., Augusteyn R.C. What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts. Clin. Exp. Optom. 2002;85(2):61–75. DOI: 10.1111/j.1444-0938.2002.tb03011.x
12. Becker B. Intraocular pressure response to topical corticosteroids. Invest. Ophthalmol. 1965;26(4):198–205.
13. Armaly M.F. The heritable nature of dexamethasone-induced ocular hypertension. Arch. Ophthalmol. 1966;75(1):32–35. DOI: 10.1001/ archopht.1966.00970050034007
14. Armaly M.F. Inheritance of dexamethasone hypertension and glaucoma. Arch. Ophthalmol. 1967;77(6):747–751. DOI: 10.1001/archopht.1967.00980020749006
15. Godel V., Feiler-Ofry V., Stein R. Systemic steroids and ocular fl uid dynamics. II. Systemic versus topical steroids. Acta Ophthalmol. (Copenh). 1972;50(5):664–676. DOI: 10.1111/j.1755-3768.1972. tb06607.x
16. Clark A.F. Steroids, ocular hypertension, and glaucoma. J. Glaucoma. 1995;4(5):354–369. DOI: 10.1097/00061198-199510000-00010
17. Clark A.F., Wilson K., de Kater A.W. et al. Dexamethasone-induced ocular hypertension in perfusion-cultured human eyes. Invest. Ophthalmol. Vis. Sci. 1995;36(2):478–489
18. Vranka J.A., Kelley M.J., Acott T.S., Keller K.E. Extracellular matrix in the trabecular meshwork: intraocular pressure regulation and dysregulation in glaucoma. Exp. Eye Res. 2015;133:112–125. DOI: 10.1016/j.exer.2014.07.014
19. Comes N., Buie L.K., Borrás T. Evidence for a role of angiopoietin-like 7 (ANGPTL7) in extracellular matrix formation of the human trabecular meshwork: implications for glaucoma. Genes Cells. 2011;16(2):243–259. DOI: 10.1111/j.1365-2443.2010.01483.x
20. Francois J., Victoria-Troncoso V. Mucopolysaccharides and pathogenesis of cortisone glaucoma. Klin. Monatsbl. Augenheilkd. 1974;165(1):5–10.
21. Steely H.T., Browder S.L., Julian M.B. et al. The eff ects of dexamethasone on fi bronectin expression in cultured human trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 1992;33(7):2242–2250.
22. Fan B.J., Wang D.Y., Tham C.C. et al. Gene expression profi les of human trabecular meshwork cells induced by triamcinolone and dexamethasone. Invest. Ophthalmol. Vis. Sci. 2008;49(5):1886– 1897. DOI: 10.1167/iovs.07-0414
23. Tripathi B.J., Tripathi R.C., Swift H.H. Hydrocortisone-induced DNA endoreplication in human trabecular cell in vitro. Exp. Eye Res. 1989;49:259–270. DOI: 10.1016/0014-4835(89)90095-x
24. Zhang X., Clark A.F., Yorio T. FK506-binding protein 51 regulates nuclear transport of the glucocorticoid receptor beta and glucocorticoid responsiveness. Invest. Ophthalmol. Vis. Sci. 2008;49(3):1037– 1047. DOI: 10.1167/iovs.07-1279
25. Singh I.P., Ahmad S.I., Yeh D. et al. Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2004;138(2):286–287. DOI: 10.1016/j.ajo.2004.03.001
26. Becker B., Hahn K.A. Topical corticosteroids and heredity in primary open-angle glaucoma. Am J Ophthalmol. 1964;54:543–551. DOI: 10.1016/0002-9394(64)92500-0
27. Armaly M.F. Statistical attributes of the steroid hypertensive response in the clinically normal eye. 1. The demonstration of three level of response. Investigative Ophthalmology & Visual Science. 1965;4(2):187–197.
28. Schwartz J.T., Reuling F.H., Feinlieb M. et al. Twin study on ocu lar pressure following topically applied dexamethasone: II. Inheritance of variation in pressure response. Arch. Ophthalmol. 1973;90(4):281– 286. DOI:10.1001/archopht.1973.01000050283006
29. Lo W.R., Rowlette L.L., Caballero M. et al. Tissue diff erential microarray analysis of dexamethasone induction reveals potential mechanisms of steroid induced glaucoma. Invest. Ophthalmol. Vis. Sci. 2003;44(2):473–485. DOI: 10.1167/iovs.02-0444
30. Wordinger R.J., Clark A.F. Eff ects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma. Prog. Retina Eye Res. 1999;18(5):629–667. DOI: 10.1016/s1350- 9462(98)00035-4
31. Alward W.L., Fingert J.H., Coote M.A. et al. Clinical features associated with mutations in the chromosome 1 open-angle glaucoma gene (GLC1A). N. Engl. J. Med. 1998;338(15):1022–1027. DOI: 10.1056/NEJM199804093381503
32. Tamm E.R. Myocilin and glaucoma: facts and ideas. Prog. Retina Eye Res. 2002;21(4):395–428. DOI: 10.1016/s1350-9462(02) 00010-1
33. Gould D.B., Miceli-Libby L., Savincva O.V. et al. Genetically increasing Myoc expression supports a necessary pathological role of abnormal proteins in glaucoma. Mol. Cell Biol. 2004;24(20):9019– 9025. DOI: 10.1128/MCB.24.20.9019-9025.2004
34. Fingert J.H., Clark A.F., Craig J.E. et al. Evaluation of the myocilin (MYOC) glaucoma gene in monkey and human steroid-induced ocular hypertension. Invest. Ophthalmol. Vis. Sci. 2001;42(1):145–152.
35. Tripathi R.C., Parapuram S.K., Tripathi B.J. et al. Corticosteroids and glaucoma risk. Drugs Aging. 1999;15(6):439–450. DOI: 10.2165/00002512-199915060-00004
36. Becker B., Mills D.W. Corticosteroids and intraocular pressure. Arch. Ophthalmol. 1963;70:(4):500–507. DOI: 10.1001/archopht.1963.00960050502012
37. Gatson H., Absolon M.J., Thurtle O.A., Sattar M.A. Steroid responsiveness in connective tissue diseases. British Journal of Ophthalmology. 1983;67(7):487–490. DOI: 10.1136/bjo.67.7.487
38. Shaikh N.M., Shaikh S., Singh K., Manche E. Progression of endstage glaucoma after laser in situ keratomileusis. J. Cataract Refract Surg. 2002;28(2):356–359. DOI: 10.1016/s0886-3350(01)01065-3
39. Hamilton D.R., Manche E.E., Rich L.F., Maloney R.K. Steroid- induced glaucoma after laser in situ keratomileusis associated with interface fl uid. Ophthalmology. 2002;109(4):659–665. DOI: 10.1016/ s0161-6420(01)01023-5
40. Weinreb R.N., Polansky J.R., Kramer S.G., Doxr J.D. Acute eff ects of dexamethasone on intraocular pressure in glaucoma. Investigative Ophthalmology & Visual Science. 1985;26(2):170–175.
41. Armaly M.F. Eff ect of corticosteroids on intraocular pressure and fl uid dynamics: I. The eff ect of dexamethasone in the normal eye. Arch. Ophthalmol. 1963;70(4):482–491. DOI: 10.1001/archopht.1963.00960050484010
42. Allingham R., Damji K.R., Freedman S. et al. Steroid-Induced Glaucoma. In: Shields Textbook of Glaucoma. 6th edition. Philadelphia, PA, USA: Lippincott Williams and Wilkins; 2011:344–349.
43. Cantrill H.L., Palmberg P.F., Zink H.A. et al. Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure. Am. J. Ophthalmol. 1975;79(6):1012–1017. DOI: 10.1016/0002- 9394(75)90687-x
44. Bernstein H.N., Schwartz B. Eff ects of long‐term systemic steroids on ocular pres‐ sure and tonographic values. Arch. Ophthalmol. 1962;68(6):742–753. DOI: 10.1001/ archopht.1962.00960030746009
45. Zugerman C., Saunders D., Levit F. Glaucoma from topically applied steroids. Arch. Dermatol. 1976;112(9):1326. DOI: 10.1001/ archderm.1976.01630330080032
46. Касимов Э.М., Агаева Ф.А. Мониторинг внутриглазного давления у пациентов с заболеваниями соединительной ткани, получающих лечение стероидами. Клиническая офтальмология. 2013;13(4):150–153.
47. Godel V., Feiler-Ofry V., Stein R. Systemic steroids and ocular fl uid dynamics. II. Systemic versus topical steroids. Acta Ophthalmol. (Copenh). 1972;50(5):664–676. DOI: 10.1111/j.1755-3768.1972.tb06606.x
48. Kaur S., Dhiman I., Kaushik S. et al. Outcome of ocular steroid hypertensive response in children. J. Glaucoma. 2016;25(4):343–347. DOI: 10.1097/ijg.0000000000000209
49. Gupta S., Shah P., Grewal S. et al. Steroid-induced glaucoma and childhood blindness. Br. J. Ophthalmol. 2015;99(11):1454–1461. DOI: 10.1136/bjophthalmol-2014-306557.
50. Ang M., Ti S.E., Loh R. et al. Steroid-induced ocular hypertension in Asian children with severe vernal keratoconjunctivitis. Clin Ophthalmol. 2012;6:1253–1258. DOI: 10.2147/OPTH.S32936
51. Bonini S., Bonini S., Lambiase A. et al. Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term follow-up. Ophthalmology. 2000;107(6):1157–1163. DOI: 10.1016/s0161- 6420(00)00092-0
52. Opatowsky I., Feldman R.M., Gross R., Fedman S.T. Intraocular pressure elevation associated with inhalation and nasal corticosteroids. Ophthalmology. 1995;102(2):177–179. DOI: 10.1016/s0161- 6420(95)31039-1
53. Garbe E., Lorier J., Boivin J.F., Siussa S. Inhaled and nasal glucocorticoids and the risk of ocular hypertension or open-angle glaucoma. JAMA. 1997;277(9):722–727. DOI: 10.1001/jama.277.9.722
54. Mitchell P., Cumming R.G., Mackey D.A. Inhaled corticosteroids, family history, and risk of glaucoma. Ophthalmology. 1999;106(12):2301–2306. DOI: 10.1016/S0161-6420(99)90530-4
55. Dreyer E.B. Inhaled steroid use and glaucoma. N. Engl. J. Med. 1993;329(24):1822. DOI: 10.1056/nejm199312093292420
56. Opatowsky I., Feldman R.M., Gross R., Fedman S.T. Intraocular pressure elevation associated with inhalation and nasal corticosteroids. Ophthalmology. 1995;102(2):177–179. DOI: 10.1016/s0161- 6420(95)31039-1
57. Nath T., Roy S.S., Kumar H. et al. Prevalence of steroid-induced cataract and glaucoma in chronic obstructive pulmonary disease patients attending a tertiary care center in India. Asia-Pacifi c J. Ophthalmol. 2017;6(1):28–32. DOI: 10.22608/APO.201616
58. Shroff S., Thomas R.K., D’Souza G., Nithyanandan S. The eff ect of inhaled steroids on the intraocular pressure. Digit. J. Ophthalmol. 2018;24(3):6–9. DOI:10.5693/djo.01.2018.04.001
59. Duh M.S., Walker A.M., Lindmark B., Laties A.M. Association between intraocular pressure and budesonide inhalation therapy in asthmatic patients. Ann. Allergy Asthma Immunol. 2000;85(5):356– 361. DOI: 10.1016/S1081-1206(10)62545-8
60. Jindal S.K., Aggarwal A.N., Gupta D. et al. Indian study on epidemiology of asthma, respiratory symptoms and chronic bronchitis in adults (INSEARCH). Int. J. Tuberc. Lung Dis. 2012;16(9):1270– 1277. DOI: 10.5588/ijtld.12.0005
61. Moss E.B., Buys Y.M., Low S.A. et al. A randomized controlled trial to determine the eff ect of inhaled corticosteroid on intraocular pressure in open-angle glaucoma and ocular hypertension: the ICOUGH Study. J. Glaucoma. 2016;26(2):182–186. DOI: 10.1097/ IJG.0000000000000429
62. Витовская О.П. Медикаментозно индуцированная глаукома. Офтальмологические ведомости. 2014;7(3):58–62. DOI: 10.17816/OV2014358‐62.. DOI: 10.17816/OV2014358‐62
63. Haller J.A., Bandello F., Belfort R. et al. Dexamethasone intravitreal implant in patients with macular oedema related to branch or central retinal vein occlusion twelve- month study results. Ophthalmology. 2011;118(12):2453–2460. DOI: 10.1016/j.ophtha.2011.05.014
64. Bollinger K., Kim J., Lowder C.Y. et al. Intraocular pressure outcome of patients with fl uocinolone acetonide intravitreal implant for noninfectious uveitis. Ophthalmology. 2011;118(10):1927–1931. DOI: 10.1016/j.ophtha.2011.02.042
65. Vedantham V. Intraocular pressure rise after intravitreal triamcinolone. Am. J. Ophthalmol. 2005;139(3):575. DOI: 10.1016/j. ajo.2004.10.023
66. Aref A.A., Scott I.U., Oden N.L. et al. Incidence, risk factors, and timing of elevated intraocular pressure after intravitreal triamcinolone acetonide injection for macular edema secondary to retinal vein occlusion: SCORE Study Report 15. JAMA Ophthalmol. 2015;133(9):1022–1029. DOI: 10.1001/jamaophthalmol.2015.1823.
67. Smithen L.M., Ober M.D., Maranan L., Spaide R.F. Intravitreal triamcinolone acetonide and intraocular pressure. Am. J. Ophthalmol 2004;138(5):740–743. DOI: 10.1016/j.ajo.2004.06.067
68. Gillies M.C., Simpson J.M., Billson F.A., Luo W. et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch. Ophthalmol. 2004;122(3):336–340. DOI: 10.1001/archopht.122.3.336
69. Jain S., Thompson J.R., Foot B. et al. Severe intraocular pressure rise following intravitreal triamcinolone: a national survey to estimate incidence and describe case profi les. Eye (Lond). 2014;28(4):399–401. DOI: 10.1038/eye.2013.306
70. Zode G.S., Sharma A.B., Lin X. et al. Ocular-specifi c ER stress reduction rescues glaucoma in murine glucocorticoid-induced glaucoma. J. Clin. Invest. 2014;124(5):1956–1965. DOI: 10.1172/JCI69774
71. Herschler J. Increased intraocular pressure induced by repository corticosteroids. Am. J. Ophthalmol. 1976;82(1):90–93. DOI: 10.1016/0002-9394(76)90669-3
72. Kitazawa Y. Increased intraocular pressure induced by corticosteroids. Am. J. Ophthalmol. 1976;82(3):492–495. DOI: 10.1016/0002- 9394(76)90500-6
73. McGhee C.N., Watson D.G., Midgley J.M. et al. Penetration of synthetic corticosteroids into human aqueous humour. Eye. 1990;4(3):526–530. DOI: 10.1038/eye.1990.70
74. Asano S., Miyake K., Ota I., Sugita G. et al. Reducing angiographic cystoid macular edema and blood-aqueous barrier disruption after small-incision phacoemulsifi cation and foldable intraocular lens implantation: Multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. J. Cataract Refract. Surg. 2008;34(1):57–63. DOI: 10.1016/j.jcrs.2007.08.030
75. Wilhelmi E. Experimental and clinical investigation of a non-hormonal anti-infl ammatory eye ointment. Ophthalmic Res. 1973;5(5):253– 289. DOI: 10.1159/000266072
76. Perry H.D., Donnenfeld E.D., Acheampong A. et al. Topical Cyclosporine A in the management of postkeratoplasty glaucoma and corticosteroid-induced ocular hypertension (CIOH) and the penetration of topical 0.5% cyclosporine A into the cornea and anterior chamber. CLAO J. 1998;24(3):159–165. DOI: 10.1097/00003226-199705000- 00005
77. Jones R., Rhee D.J. Corticosteroid‐induced ocular hypertension and glaucoma: a brief review and update of the literature. Current оpinion in оphthalmology. 2006;17(2):163–167. DOI: 10.1097/01. icu.0000193079.55240.18
78. Leibowitz H.M., Ryan W.J., Kupferman A. Comparative anti-infl ammatory effi cacy of topical corticosteroids with low glaucoma-inducing potential. Arch. Ophthalmol. 1992;110(1):118–120. DOI: 10.1001/archopht.1992.01080130120038
79. Espildora J, Vicuna P, Diaz E. Cortisone-induced glaucoma: a report on 44 aff ected eyes. J Fr. Ophthalmol 1981;4(6–7):503–508. DOI: 10.11565/arsmed.v42i24.977
80. Симакова И.Л., Куликов А.Н., Тихоновская И.А. и др. Особен ности диагностики и лечения клинического случая медика ментозно-индуцированной глаукомы. Офтальмология. 2019;16(3):399–407. DOI: 10.18008/1816-5095-2019-3-399-407
81. Goldberg I. Ocular infl ammatory and steroid-induced glaucoma. In: Yanoff M., Duker J.S. (eds) Ophthalmology, 2nd ed. Mosby: St Louis, MO, 2004;1512–1517. DOI: 10.1016/b978-0-323-04332-8.00196-7
82. Honjo M., Tanihara H., Inatani M., Honda Y. External trabeculotomy for the treatment of steroid-induced glaucoma. J. Glaucoma. 2000;9(6):483–485. DOI: 10.1097/00061198-200012000-00011
83. Scherer W.J., Hauber F.A. Eff ect of latanoprost on intraocular pressure in steroid induced glaucoma. J. Glaucoma. 2000;9(2):179–182. DOI: 10.1097/00061198-200004000-00009
84. Warwar R.E., Bullock J.D., Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology. 1998;105(2):263–268. DOI: 10.1016/s0161-6420(98)92977-3
85. DAmico D.J., Goldberg M.F., Hudson H. et al. Anecortave acetate as monotherapy for the treatment of subfoveal neovascularization in age-related macular degenerations: twelve-month clinical outcomes. Ophthalmology. 2003;110(12):2372–2383.
86. Phulke S., Kaushik S., Kaur S., Pandav S.S. Steroid-induced Glaucoma: An Avoidable Irreversible Blindness. J. Curr. Glaucoma Pract. 2017;11(2):67–72. DOI: 10.5005/jp-journals-l0028-1226
87. Galin M.A., Hirschman H., Gould H., Hofmann I. Does laser trabeculoplasty prevent steroid glaucoma? Ophthalmic Surg. Lasers. 2000;31(2):107–110. DOI: 10.3928/1542-8877-20000301-06
88. Thomas R., Jay J.L. Raised intraocular pressure with topical steroids after trabeculectomy. Grafes Arch. Clin. Exp. Ophthalmol. 1988;226(4):337–340. DOI: 10.1007/BF02172963
89. Green K., Cheeks L., Slagle T., Phillips C.I. Interaction between progesterone and mifepristerone on intraocular pressure in rabbits. Curr. Eye Res. 1989; 8(3): 317-320. DOI: 10.3109/02713688908997574
90. Southren A.L., Wandel T., Gordon G.G., Weinstein B.I. Treatment of primary open angle glaucoma with 3α,5β-tetrahydrocortisol: new therapeutic modality. J. Ocul. Pharmacol. 1994;10(1):385–391. DOI: 10.1089/jop.1994.10.385
91. Clark A.F., Wilson K., Miggans S.T., Lane D. Inhibition of dexamethasone-induced cytoskeletal changes in cultured human trabecular meshwork cells by tetrahydrocortisol. Invest. Ophthalmol. Vis. Sci. 1996;37(5):805–813.
92. Spiga M.G., Borrás T. Development of a gene therapy virus with a glucocorticoid-inducible MMP1 for the treatment of steroid glaucoma. Invest. Ophthalmol. Vis. Sci. 2010;51(6):3029–3041. DOI: 10.1167/iovs.09-4918
93. Tektas O.Y., Hammer C.M., Danias J. et al. Morphologic changes in the outfl ow pathways of bovine eyes treated with corticosteroids. Invest. Ophthalmol. Vis. Sci. 2010;51:4060–4066. DOI: 10.1167/ iovs.09-4742
Рецензия
Для цитирования:
Нагорнова З.М., Селезнев А.В., Булах И.А., Брежнев А.Ю., Куроедов А.В. Стероидная глаукома. Клиническая медицина. 2021;99(7-8):420-428. https://doi.org/10.30629/0023-2149-2021-99-7-8-420-428
For citation:
Nagornova A.M., Seleznеv A.V., Bulakh I.A., Brezhnev A.Yu., Kuroyedov A.V. Steroid glaucoma. Clinical Medicine (Russian Journal). 2021;99(7-8):420-428. (In Russ.) https://doi.org/10.30629/0023-2149-2021-99-7-8-420-428
Просмотров:
1142
Послать статью по эл. почте 